NCT02798172View on ClinicalTrials.gov

The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

NACompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Alogliptin and Metformin

The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)

All Listed Sponsors
lead

Fourth People's Hospital of Shenyang

OTHER

NCT02798172 - The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy | Biotech Hunter | Biotech Hunter